Implanted blood access devices are essential for patients requiring long-term hemodialysis, providing reliable vascular access while maintaining blood integrity. One of the most critical safety concerns is blood cell damage — including hemolysis, platelet activation, and leukocyte depletion — which can compromise treatment effectiveness and patient outcomes. That’s why ISO 18193 requires rigorous evaluation of blood compatibility as part of device validation.
At our laboratory, we conduct Blood Cell Damage testing in full compliance with ISO 18193, ensuring every device is assessed under clinically relevant conditions to meet international standards.